Home › Employers › Genetix Biotherapeutics Inc.
Genetix Biotherapeutics Inc.: H-1B salaries and sponsorship
Genetix Biotherapeutics Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $170,000.
Does Genetix Biotherapeutics Inc. sponsor H-1B visas?
Genetix Biotherapeutics Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 29, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Director, Translational Biomarkers | 1 | $205,000 |
| Senior Scientist | 1 | $144,200 |
| Associate Director, Pharmacovigilance-Medical Affairs | 1 | $170,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2026 | 3 | $170,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Associate Director, Pharmacovigilance-Medical Affairs | $170,000–$200,000 Level IV | Somerville, MA | Apr 29, 2026 | Apr 30, 2026 | Certified |
| Senior Scientist | $144,200–$194,700 Level III | Somerville, MA | Nov 24, 2025 | Feb 10, 2026 | Certified |
| Director, Translational Biomarkers | $205,000–$254,000 Level III | Somerville, MA | Nov 24, 2025 | Mar 23, 2026 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).